BACKGROUND: Interferon-gamma (IFN-gamma) production by lymphocytes exposed to antigens specific of Mycobacterium tuberculosis has been shown to correlate with antigen load and disease activity. AIM OF STUDY: To determine whether treatment of tuberculosis (TB) led to a decrease and/or a reversion of results of a IFN-gamma release assay (T-SPOT.TB, Oxford Immunotec, UK) and thus if T-SPOT.TB could be used to monitor response to treatment. METHODS: Qualitative and quantitative analysis (SFUs: spot-forming units) of T-SPOT.TB in HIV-negative patients with TB, during initial 2 weeks of treatment (T0), at end of treatment (TE) and 6 months later (TE+6). RESULTS: Mean SFU (SD) was 75 (58; n=62) at T0, 46 (55; n=55) at TE, and 33 (46; n=41) at TE+6; positive rate was 98%, 93% and 98%, respectively. SFUs (paired samples, n=36) decreased significantly between T0 and TE; 2 reversions occurred between T0 and TE (6%), but none between TE and TE+6. Of 6 patients (17%) with an increase in SFUs between T0 and TE, 5 had a favourable outcome at TE and TE+6. CONCLUSION: Decrease in SFUs under treatment suggests a relationship with antigen load; however, persisting high SFUs were not predictive of unfavourable outcome and test reversion was rare.
BACKGROUND: Interferon-gamma (IFN-gamma) production by lymphocytes exposed to antigens specific of Mycobacterium tuberculosis has been shown to correlate with antigen load and disease activity. AIM OF STUDY: To determine whether treatment of tuberculosis (TB) led to a decrease and/or a reversion of results of a IFN-gamma release assay (T-SPOT.TB, Oxford Immunotec, UK) and thus if T-SPOT.TB could be used to monitor response to treatment. METHODS: Qualitative and quantitative analysis (SFUs: spot-forming units) of T-SPOT.TB in HIV-negative patients with TB, during initial 2 weeks of treatment (T0), at end of treatment (TE) and 6 months later (TE+6). RESULTS: Mean SFU (SD) was 75 (58; n=62) at T0, 46 (55; n=55) at TE, and 33 (46; n=41) at TE+6; positive rate was 98%, 93% and 98%, respectively. SFUs (paired samples, n=36) decreased significantly between T0 and TE; 2 reversions occurred between T0 and TE (6%), but none between TE and TE+6. Of 6 patients (17%) with an increase in SFUs between T0 and TE, 5 had a favourable outcome at TE and TE+6. CONCLUSION: Decrease in SFUs under treatment suggests a relationship with antigen load; however, persisting high SFUs were not predictive of unfavourable outcome and test reversion was rare.
Authors: Thomas J Scriba; Chelsea Carpenter; Sebastian Carrasco Pro; John Sidney; Munyaradzi Musvosvi; Virginie Rozot; Grégory Seumois; Sandy L Rosales; Pandurangan Vijayanand; Delia Goletti; Edward Makgotlho; Willem Hanekom; Mark Hatherill; Bjoern Peters; Alessandro Sette; Cecilia S Lindestam Arlehamn Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley Journal: BMC Infect Dis Date: 2010-05-27 Impact factor: 3.090
Authors: Ifedayo M O Adetifa; Martin O C Ota; Brigitte Walther; Abdulrahman S Hammond; Moses D Lugos; David J Jeffries; Simon A Donkor; Richard A Adegbola; Philip C Hill Journal: PLoS One Date: 2010-09-01 Impact factor: 3.240
Authors: David T Mzinza; Derek J Sloan; Kondwani C Jambo; Doris Shani; Mercy Kamdolozi; Katalin A Wilkinson; Robert J Wilkinson; Geraint R Davies; Robert S Heyderman; Henry C Mwandumba Journal: Tuberculosis (Edinb) Date: 2015-05-28 Impact factor: 3.131
Authors: Jordan L Mitchell; Conor O'Halloran; Paul Stanley; Kieran McDonald; Paul Burr; Danièlle A Gunn-Moore; Jayne C Hope Journal: Pathogens Date: 2021-05-26